SOX9 and non-small cell lung carcinoma: Evodiamine can treat non-small cell lung cancer (NSCLC) by down-regulating the expression of SOX-9 and β-catenin and significantly inhibiting cell migration by inhibiting epithelial-mesenchymal transition (EMT) (Panda M. et al., 2024).